{"entity":{"id":"azd0120","kind":"drug","name":"AZD0120","aka":[],"tldr":"AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.","summary":"AZD0120 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 3 trials sponsored by AstraZeneca and Alexion Pharmaceuticals, Inc., in multiple myeloma. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of AZD0120","url":"https://clinicaltrials.gov/search?intr=AZD0120"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["cd19","bcma"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07391657","nct07764978"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"AZD0120","modality":"CAR-T cell therapy","mechanism":"A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd0120/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/"},{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/"},{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/"}]}}